Press Releases
May 7, 2020
Washington, D.C. – As the pandemic worsens in Texas and yet Gov. Abbott pushes forward in pressing workers to return to their workplaces, U.S. Representative Lloyd Doggett (D-TX), Chairman of the Health Subcommittee on Ways and Means, released the following statement regarding Governor Abbott’s visit to the White House today:
Issues:Coronavirus (COVID-19)
May 7, 2020
Austin, T.X. – As the COVID-19 pandemic worsens and many Texans approach two months since job loss—the deadline to enroll in an ACA Marketplace plan for someone who lost their coverage when they lost their job—U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, will hold a virtual press conference this afternoon to share the steps consumers need to take (and when to take them) to get covered, local resources available, and important updates on Medicaid.
Issues:Coronavirus (COVID-19)
May 6, 2020
Austin, T.X. – As the COVID-19 pandemic worsens and many Texans approach two months since job loss—the deadline to enroll in an ACA Marketplace plan for someone who lost their coverage when they lost their job—U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, will hold a virtual press conference tomorrow to share the steps consumers need to take (and when to take them) to get covered, local resources available, and important updates on Medicaid.
May 5, 2020
Washington, D.C. – U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, issued the following statement reacting to President Trump’s winding down the Coronavirus Task Force:
Issues:Coronavirus (COVID-19)
May 5, 2020
Washington, D.C. – U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, issued the following statement in reaction to Dr. Rick Bright’s whistleblower complaint:
Issues:Coronavirus (COVID-19)
May 5, 2020
Washington, D.C. – As many college students and their families are facing financial difficulties that may impact their ability to return to class this fall, U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, is introducing the American Opportunity Student Tax Relief Act, joined by U.S. Representative Brian Fitzpatrick (R-PA). This legislation assures that college emergency grants to students authorized by the CARES Act are not taxed. It expands the American Opportunity Tax Credit (AOTC)—which already helps millions of students pay for the costs of college—with both a short-term expansion of the incentive during the pandemic and long-term improvements to the program.
Issues:Coronavirus (COVID-19)
May 4, 2020
Washington, D.C. – Today, U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, led Members in urging Gilead CEO Daniel O’Day to detail the company’s plans for remdesivir, including securing and scaling up the supply chain, complete disclosures of taxpayer investment in the development of the drug, and purchase and pricing arrangements. As remdesivir—which has been developed with significant taxpayer investment—receives FDA emergency use authorization, the lawmakers questioned its affordability and accessibility for patients.
May 4, 2020
Washington, D.C. – As the COVID-19 pandemic places unique pressures on food supply chains in the United States, U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, led Members in urging the Department of Agriculture to curb the extreme measures for “depopulation” at some animal slaughter facilities. Their letter raises concerns about mass suffocation of animals who are being quickly cleared from facilities and urges use of more humane practices.
May 4, 2020
Washington, D.C. – Following today’s Food and Drug Administration (FDA) announcement of changes in requirements for antibody tests, U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, released the following statement:
Issues:Coronavirus (COVID-19)
May 1, 2020
Washington, D.C. – Amid announcements concerning preliminary clinical trial data on remdesivir and anticipated emergency use authorization from the FDA, U.S. Representative Lloyd Doggett (D-TX), Chair of the House Ways and Means Health Subcommittee, and Rep. Rosa DeLauro (D-CT), Chair of the Labor, Health and Human Services, and Education Appropriations Subcommittee, urge Secretary Azar to release information about the extent of taxpayer investment in remdesivir, government ownership of any remdesivir patents, and any federal efforts to scale-up production. Arguing that an unaffordable drug is entirely ineffective for patients suffering, the members assert that “substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized.”
Issues:Coronavirus (COVID-19)